Molecular changes evoked by triethylenetetramine treatment in the extracellular matrix of the heart and aorta in diabetic rats

Molecular Pharmacology

Volumn 70, Issue 6, 2006, Pages 2045-2051

  Gong, Deming ^a   Lu, Jun ^a   Chen, Xiuyin ^a   Choong, Soon Y ^a   Zhang, Shaoping ^a,b   Chan, Yih Kai ^a   Glyn Jones, Sarah ^a   Gamble, Gregory D ^c   Phillips, Anthony R J ^a   Cooper, Garth J S ^a,b,c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; CUPRIC ION; FIBRONECTIN; FIBRONECTIN 1; GLUCOSE; HEPARAN SULFATE; SCLEROPROTEIN; SMAD4 PROTEIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; TRIENTINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DISEASE; ARTICLE; CHELATION; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEART LEFT VENTRICLE; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; UPREGULATION;

ANIMALS; AORTA; BASE SEQUENCE; BLOTTING, WESTERN; CHELATING AGENTS; COPPER; DIABETES MELLITUS, EXPERIMENTAL; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HEART; HUMANS; MALE; POLYMERASE CHAIN REACTION; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SMAD PROTEINS; SUPEROXIDE DISMUTASE; SUPEROXIDES; TRANSFORMING GROWTH FACTOR BETA;

EID: 33751081836     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.028605     Document Type: Article

References (36)

1. Akahori H, Ota T, Torita M, Ando H, Kaneko S, and Takamura T (2005) Tranilast prevents the expression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression. J Pharmacol Exp Ther 314:514-521.
2. Askari FK, Dick R, Mao M, and Brewer GJ (2004) Tetrathiomolybdate therapy protects against concanavalin and carbon tetrachloride hepatic damage in mice. Exp Biol Med 229:857-863.
3. Brewer GJ (2005) Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer. Curr Cancer Drug Targets 5:195-202.
4. Brewer GJ, Dick R, Ullenbruch MR, Jin H, and Phan SH (2004) Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 98:2160-2167.
5. Brewer GJ, Ullenbruch MR, Dick R, Olivarez L, and Phan SH (2003) Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 141:210-216.
6. Castellot JJ, Addonizio ML, Rosenberg R, and Karnovsky MJ (1981) Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J Cell Biol 90:372-379.
7. Ciechanowski K, Kedzierska K, Herdzik E, Bober J, Domanski L, Borowiak K, Rozanski J, and Myslak M (2003) Long-term hyperglycaemia decreases vascular fraction of extracellular superoxide dismutase. Diabetologia 46:1026-1027.
8. Cooper GJ, Chan YK, Dissanayake AM, Leahy FE, Keogh GF, Frampton CM, Gamble GD, Brunton DH, Baker JR, and Poppitt SD (2005) Demonstration of a hyperglycemia-driven pathogenic abnormality of copper homeostasis in diabetes and its reversibility by selective chelation: quantitative comparisons between the biology of copper and eight other nutritionally essential elements in normal and diabetic individuals. Diabetes 54:1468-1476.
9. Cooper GJ, Phillips AR, Choong SY, Leonard BL, Crossman DJ, Brunton DH, Saafi EL, Dissanayake AM, Cowan BR, Young AA, et al. (2004) Regeneration of the heart in diabetes by selective copper chelation. Diabetes 53:2501-2508.
10. Edwards IJ, Wagner JD, Vogl-Willis CA, Litwak KN, and Cefalu WT (2004) Arterial heparan sulfate is negatively associated with hyperglycemia and atherosclerosis in diabetic monkeys. Cardiovasc Diabetol 3:6.
11. Fattman CL, Schaefer LM, and Oury TD (2003) Extracellular superoxide dismutase in biology and medicine. Free Radic Biol Med 35:236-256.
12. Fraústo da Silva JJ and Williams RJ (2001) The Biological Chemistry of the Elements: The Inorganic Chemistry of Life. Clarendon Press, Oxford, UK.
13. Marklund SL (1984a) Extracellular superoxide dismutase and other superoxide dismutase isoenzymes in tissues from nine mammalian species. Biochem J 222:649-655.
14. Marklund SL (1984b) Extracellular superoxide dismutase in human tissues and human cell lines. J Clin Investig 74:1398-1403.
15. Marklund SL (1992) Regulation by cytokines of extracellular superoxide dismutase and other superoxide dismutase isoenzymes in fibroblasts. J Biol Chem 267:6696-6701.
16. Marklund SL (2002) Extracellular superoxide dismutase. Methods Enzymol 349:74-80.
17. Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, Krum H, Wilkinson-Berka J, and Gilbert RE (2005) Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-β. Cardiovasc Res 65:694-701.
18. Nicholas SB, Aguiniga E, Ren Y, Kim J, Wong J, Govindarajan N, Noda M, Wang W, Kawano Y, Collins A, et al. (2005) Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 67:1297-1307.
19. Nugent MA, Karnovsky MJ, and Edelman ER (1993) Vascular cell-derived heparan sulfate shows coupled inhibition of basic fibroblast growth factor binding and mitogenesis in vascular smooth muscle cells. Circ Res 73:1051-1060.
20. Omoto A, Kawahito Y, Prudovsky I, Tubouchi Y, Kimura M, Ishino H, Wada M, Yoshida M, Kohno M, Yoshimura R, et al. (2005) Copper chelation with tetrathiomolybdate suppresses adjuvant-induced arthritis and inflammation-associated cachexia in rats. Arthritis Res Ther 7:R1174-R1182.
21. Oury TD, Day BJ, and Crapo JD (1996) Extracellular superoxide dismutase: a regulator of nitric oxide bioavailability. Lab Investig 75:617-636.
22. Roberts AB, McCune BK, and Dunn SR (1992) TGF-β: regulation of extracellular matrix. Kidney Int 41:557-559.
23. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, and Thorgeirsson SS (1995) Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA 92:2572-2576.
24. Sandstrom J, Karlsson K, Edlund T, and Marklund SL (1993) Heparin-affinity patterns and composition of extracellular superoxide dismutase in human plasma and tissues. Biochem J 294:853-857.
25. Schnaper HW, Barnathan ES, Mazar A, Maheshwari S, Ellis S, Cortez SL, Baricos WH, and Kleinman HK (1995) Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol 165:107-118.
26. Sharma K and Ziyadeh FN (1995) Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-β as a key mediator. Diabetes 44:1139-1146.
27. Sicree R, Shaw J, Zimmet P, and Tapp R (2003) The global burden of diabetes, in Diabetes Atlas 2003 (Gan D ed), International Diabetes Federation, Brussels, Belgium.
28. Sista AK, O'Connell MK, Hinohara T, Oommen SS, Fenster BE, Glassford AJ, Schwartz EA, Taylor CA, Reaven GM, and Tsao PS (2005) Increased aortic stiffness in the insulin-resistant Zucker fa/fa rat. Am J Physiol 288:H133-H141.
29. Sivaram P, Obunike JC, and Goldberg IJ (1995) Lysolecithin-induced alteration of subendothelial heparan sulfate proteoglycans increases monocyte binding to matrix. J Biol Chem 270:29760-29765.
30. Stralin P, Jacobsson H, and Marklund SL (2003) Oxidative stress, NO and smooth muscle cell extracellular superoxide dismutase expression. Biochim Biophys Acta 1619:1-8.
31. Stroschein SL, Wang W, and Luo K (1999) Cooperative binding of Smad proteins to two adjacent DNA elements in the plasminogen activator inhibitor-1 promoter mediates transforming growth factor β-induced Smad-dependent transcriptional activation. J Biol Chem 274:9431-9441.
32. Struthers AD and Morris AD (2002) Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths. Lancet 359:1430-1432.
33. Venugopal J, Hanashiro K, Yang ZZ, and Nagamine Y (2004) Identification and modulation of a caveolae-dependent signal pathway that regulates plasminogen activator inhibitor-1 in insulin-resistant adipocytes. Proc Natl Acad Sci USA 101:17120-17125.
34. Vogl-Willis CA and Edwards IJ (2004) High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. Biochim Biophys Acta 1672:36-45.
35. Williams B (1998) Mechanical influences on vascular smooth muscle cell function. J Hypertens 16:1921-1929.
36. Yokoyama H, Sato K, Okudaira M, Morita C, Takahashi C, Suzuki D, Sakai H, and Iwamoto Y (1999) Serum and urinary concentrations of heparan sulfate in patients with diabetic nephropathy. Kidney Int 56:650-658.